

Introduction

- High fat diet (HFD) accelerates atherosclerosis.
- Atherosclerosis narrows arterial lumen, reduces blood flow and can cause hypoxia which impairs blood-brain barrier (BBB), contribute to gliosis and neurodegeneration, particularly in the hippocampus.
- Navitoclax (ABT263), an experimental senolytic, was uncovered in preclinical studies to reduce and stabilize atherosclerotic plaques.
- Senolytics specifically remove senescent cells (i.e., aged cells that no longer divide and may play a role in the development of age-related pathology).


Hypothesis: *Navitoclax will upregulate genes for BBB tight junction proteins and downregulate genes linked to gliosis, amyloid-beta (A β) and tau production in a pig model of familial hypercholesterolemia (FH) and atherosclerosis.*

Materials and Methods

A total of 15 female Rapacz-FH pigs divided into **Groups:**


- 1. Basal (3 months HFD – No treatment)
- 2. Mock (6 months HFD – Vehicle)
- 3. ABT (6 months HFD – Navitoclax)

Experimental protocol:




Results


Genes for BBB Tight Junction proteins




Gene related to Tau production



Glial Genes



Genes related to A β production



Conclusion and Next Steps

In female Rapacz-FH pigs, Navitoclax does not decrease hippocampal the expression of genes related to BBB tight junction proteins, glia, A β and tau production. Additionally, Claudin-5 and GFAP, chronic HFD does not significantly alter genes involved in BBB tight junction proteins, glia, A β and tau production.

Next steps: Repeat the RT-PCR experiments for reproducibility. Histologically quantify BBB tight junction proteins, reactive astrocytes and microglia; A β and tau.